Novartis update

On May 8, 2015 Novartis announced that Zykadia (ceritinib) was approved by the European Commission to treat ALK+ lung cancer patients previously treated with Crizotinib.

This entry was posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer. Bookmark the permalink.

Leave a Reply